Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price shot up 2.8% on Wednesday . The stock traded as high as $49.81 and last traded at $49.73, with a volume of 209,003 shares changing hands. The stock had previously closed at $48.38.

Several research firms have weighed in on FPRX. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Jefferies Group reissued a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Five Prime Therapeutics in a research note on Monday, April 18th. Leerink Swann reissued a “buy” rating and issued a $45.00 target price on shares of Five Prime Therapeutics in a research note on Friday, July 15th. Finally, Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $45.67.

The stock has a market capitalization of $1.32 billion and a price-to-earnings ratio of 5.52. The stock has a 50-day moving average price of $43.23 and a 200-day moving average price of $39.93.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.22. The business had revenue of $6.50 million for the quarter, compared to analyst estimates of $5.26 million. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm’s quarterly revenue was up 51.2% compared to the same quarter last year. Analysts anticipate that Five Prime Therapeutics Inc. will post ($2.35) EPS for the current year.

Several hedge funds and institutional investors have modified their holdings of FPRX. ProShare Advisors LLC raised its position in shares of Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock worth $1,055,000 after buying an additional 3,682 shares during the period. Russell Frank Co acquired a new position in shares of Five Prime Therapeutics during the fourth quarter worth approximately $1,265,000. California State Teachers Retirement System raised its position in shares of Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock worth $1,744,000 after buying an additional 2,842 shares during the period. Finally, Marshall Wace LLP raised its position in shares of Five Prime Therapeutics by 43.0% in the fourth quarter. Marshall Wace LLP now owns 237,141 shares of the company’s stock worth $9,841,000 after buying an additional 71,262 shares during the period.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.